A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol

BACKGROUND: About 20% of patients with primary breast cancer develop metastatic disease during the course of the disease. At this point the disease is considered incurable and thus treatment is aimed at palliation and life prolongation. As many patients will have received both an anthracycline and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kümler, Iben, Balslev, Eva, Stenvang, Jan, Brünner, Nils, Nielsen, Dorte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342210/
https://www.ncbi.nlm.nih.gov/pubmed/25885574
http://dx.doi.org/10.1186/s12885-015-1072-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342210/
https://www.ncbi.nlm.nih.gov/pubmed/25885574
http://dx.doi.org/10.1186/s12885-015-1072-9

Ejemplares similares